MedTrace Logo

Cisplatin and Pemetrexed With Radiation Followed by Lobectomy

NCT01373463 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2012-07-26

No results posted yet for this study

Summary

This study is open to patients that have been diagnosed with non-squamous Stage III Non Small Cell Lung Cancer (NSCLC) and will have surgery to remove the tumor.

The purpose of this study is to:

* Test a combination of two chemotherapeutic drugs along with radiation therapy, when given prior to surgery and see what effects (good or bad) it has on someone with this type of cancer. Chemotherapeutic drugs selectively destroy diseased cancer cells and tissues.
* Test the safety of different dose levels of radiation when given with each combination of chemotherapy;
* Determine what side effects are associated with combining radiation with these two chemotherapy combinations.

Conditions

  • Nonsquamous Nonsmall Cell Neoplasm of Lung
  • Nonsmall Cell Lung Cancer Stage III

Interventions

DRUG

Pemetrexed

Pemetrexed by vein every 21 days for 3 cycles

DRUG

Carboplatin

Carboplatin by vein Every 21 days for 3 cycles

RADIATION

Radiation Therapy

Radiation treatment 5 days a week for 5-6 weeks.

DRUG

Pemetrexed

Pemetrexed by vein every 21 days for 3 cycles

DRUG

Cisplatin

Cisplatin by vein every 21 days for 3 cycles

RADIATION

Radiation Therapy

Radiation treatment 5 days a week for 5-6 weeks.

PROCEDURE

Lobectomy

Surgery

PROCEDURE

Lobectomy

Surgery to remove a portion of the lung where the tumor is located.

Sponsors & Collaborators

  • Medical University of South Carolina

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01373463 on ClinicalTrials.gov